Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
OHE long has been involved in analysing the nature of innovation and the effects of regulation. Two recent OHE presentations address the core issues.
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
Launched at a seminar in his honour May 2014, Portrait of a Health Economist: Essays by Colleagues and Friends of Bengt Jönsson is an impressive collection…
Interdependencies in Funding Medical Research in the UK
2 July 2014
Cancer Research UK has recently released a report completed for it by OHE and the Science Policy Research Unit (SPRU) at the University of Sussex that…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value…
Innovation in Oncology: Real Option Value and Path Dependence
29 April 2014
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward…
Defining the Complementarity of Medical Research Across Sectors in the UK
11 March 2014
Under an MRC grant, OHE is collaborating to estimate in monetary terms the synergies of medical research spending in the UK by the pharma industry, charities…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…